Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient

Louis Weinstein, Chhanda Bewtra, J. Chris Gallagher

Research output: Contribution to journalArticlepeer-review

109 Scopus citations

Abstract

Menopause constitutes a sizable proportion of the adult woman's life, and it is reasonable to consider that most women will benefit from hormone-replacement therapy. Also, it is important to realize that cardiovascular disease is a major cause of morbidity and death in the menopausal patient. Two regimens of hormone-replacement therapy were evaluated in postmenopausal women with 0.625 mg of conjugated equine estrogen with either 2.5 or 5 mg of medroxyprogesterone acetate taken continuously for 52 weeks in 92 patients. The data demonstrated an improvement in menopausal symptoms, a beneficial effect in lipoprotein profiles, the establishment of an atrophic endometrium, and a marked decrease in vaginal bleeding after 13 weeks and a further decrease after 26 weeks. Ideally this regimen will offer better patient compliance and, if the favorable lipoprotein profiles offer protection to the cardiovascular system, the overall health of the American woman will be markedly affected.

Original languageEnglish (US)
Pages (from-to)1534-1542
Number of pages9
JournalAmerican Journal of Obstetrics and Gynecology
Volume162
Issue number6
DOIs
StatePublished - Jun 1990

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient'. Together they form a unique fingerprint.

Cite this